Nutriband Inc (NTRB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nutriband Inc (NTRB) has a cash flow conversion efficiency ratio of -0.232x as of October 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.75 Million) by net assets ($7.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nutriband Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Nutriband Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Nutriband Inc total liabilities for a breakdown of total debt and financial obligations.
Nutriband Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nutriband Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Perusahaan Sadur Timah Malaysia Perstima Bhd
KLSE:5436
|
0.069x |
|
Plastiblends India Limited
NSE:PLASTIBLEN
|
-0.001x |
|
Wolford Aktiengesellschaft
VI:WOL
|
0.055x |
|
Visi Media Asia Tbk
JK:VIVA
|
0.067x |
|
SolTech Energy Sweden AB
ST:SOLT
|
-0.098x |
|
Topmix Berhad
KLSE:0302
|
-0.004x |
|
DiGiSPICE Technologies Limited
NSE:DIGISPICE
|
0.317x |
|
Madusari Murni Indah Tbk PT
JK:MOLI
|
0.070x |
Annual Cash Flow Conversion Efficiency for Nutriband Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Nutriband Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Nutriband Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-01-31 | $6.43 Million | $-4.63 Million | -0.720x | -31.36% |
| 2024-01-31 | $6.44 Million | $-3.53 Million | -0.548x | -57.24% |
| 2023-01-31 | $8.57 Million | $-2.99 Million | -0.348x | -47.10% |
| 2022-01-31 | $11.86 Million | $-2.81 Million | -0.237x | -467.13% |
| 2021-01-31 | $7.11 Million | $-297.06K | -0.042x | +99.18% |
| 2020-01-31 | $175.43K | $-894.47K | -5.099x | -1009.06% |
| 2019-01-31 | $2.40 Million | $-1.11 Million | -0.460x | +39.84% |
| 2018-01-31 | $121.51K | $-92.86K | -0.764x | +88.06% |
| 2017-01-31 | $23.11K | $-147.92K | -6.401x | -149.63% |
| 2016-01-31 | $-11.47K | $-147.92K | 12.897x | -- |
About Nutriband Inc
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA b… Read more